2016
ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II
Dhakal S, Advani R, Ballas LK, Dabaja BS, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Younes A, Constine LS. ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II. American Journal Of Clinical Oncology 2016, 39: 535-544. PMID: 27643717, PMCID: PMC7433865, DOI: 10.1097/coc.0000000000000331.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyDisease-Free SurvivalDose-Response Relationship, DrugFemaleHodgkin DiseaseHumansMaleNeoplasm InvasivenessNeoplasm StagingOutcome Assessment, Health CarePractice Guidelines as TopicRadiotherapy DosageRandomized Controlled Trials as TopicRisk AssessmentSocieties, MedicalSurvival AnalysisUnited StatesConceptsStage IModality therapyHodgkin's lymphomaAppropriateness CriteriaMedical literatureAppropriateness of imagingACR Appropriateness CriteriaRadiology Appropriateness CriteriaEvidence-based guidelinesMultidisciplinary expert panelSpecific clinical conditionsSpecific clinical scenariosCurrent medical literatureRecent medical literatureLess chemotherapyPeer-reviewed journalsLate effectsClinical conditionsRadiation therapyAmerican CollegeExpert opinionClinical scenariosExcellent efficacyGuideline developmentAvailable evidence
2012
Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults
Omer B, Kadan‐Lottick N, Roberts KB, Wang R, Demsky C, Kupfer GM, Cooper D, Seropian S, Ma X. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults. British Journal Of Haematology 2012, 158: 615-625. PMID: 22775513, DOI: 10.1111/j.1365-2141.2012.09211.x.Peer-Reviewed Original ResearchConceptsSecond malignant neoplasmsStandardized incidence ratiosSolid second malignant neoplasmsExtended field radiotherapyRecent treatment optionsLow-dose radiationSMN riskSubsequent malignanciesModality therapyIncidence ratiosHodgkin's lymphomaTreatment optionsMalignant neoplasmsSubgroup analysisCMT groupLower incidenceHigh riskGeneral populationAlkylator chemotherapyPatientsDose radiationRiskRadiotherapyChildrenAdults
2000
Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy
Elconin J, Roberts K, Rizzieri D, Vermont C, Clough R, Kim C, Dodge R, Prosnitz L. Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy. International Journal Of Radiation Oncology • Biology • Physics 2000, 48: 1097-1105. PMID: 11072168, DOI: 10.1016/s0360-3016(00)00695-7.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleHodgkin DiseaseHumansMaleMechlorethamineMediastinal NeoplasmsMiddle AgedNeoplasm StagingPrednisoneProcarbazineRadiotherapy DosageRetrospective StudiesTreatment FailureVinblastineVincristineConceptsLarge mediastinal adenopathyHodgkin's disease patientsComplete responseDisease patientsInduction chemotherapyInduction failureGallium scanMediastinal adenopathyModality therapyRT doseComplete clinical stagingLow-dose radiotherapyResidual radiographic abnormalitiesCycles of chemotherapyFailure-free survivalPhase III trialsPatterns of failureConsolidation radiationChemotherapy regimensCR patientsIII trialsOverall survivalClinical stagingHD patientsRadiographic abnormalities
1999
135 Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy
Elconin J, Roberts K, Vermont C, Rizzeri D, Clough R, Prosnitz L. 135 Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy. International Journal Of Radiation Oncology • Biology • Physics 1999, 45: 216. DOI: 10.1016/s0360-3016(99)90153-0.Peer-Reviewed Original Research
1995
Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study.
Salloum E, Doria R, Farber L, Roberts K, Cooper D. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study. The Cancer Journal 1995, 1: 267-73. PMID: 9166487.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleFollow-Up StudiesHodgkin DiseaseHumansMaleMechlorethamineMiddle AgedNeoplasm Recurrence, LocalNeoplasms, Second PrimaryPrednisoneProcarbazineRemission InductionSalvage TherapyTime FactorsTreatment OutcomeVinblastineVincristineConceptsFailure-free survivalStage IV diseaseAdvanced Hodgkin's diseaseDisease-free survivalHodgkin's diseaseComplete remissionSecond malignanciesRadiation therapyLong-term disease-free survivalInvolved-field radiation therapyDurable second remissionsMOPP/ABVDRecurrent Hodgkin's diseaseInitial complete remissionCombined modality therapyMonths of chemotherapyLong-term resultsResults of treatmentSalvage therapySecond remissionInitial remissionUntreated patientsModality therapyOverall survivalChemotherapy program
1992
Combined chemotherapy and radiotherapy for Hodgkin's disease.
Prosnitz L, Roberts K. Combined chemotherapy and radiotherapy for Hodgkin's disease. Oncology 1992, 6: 113-28; discussion 131-2, 137. PMID: 1533138.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseCombined chemotherapyIntermediate-stage Hodgkin's diseaseSecond malignant neoplasmsStage Hodgkin's diseaseAdvanced Hodgkin's diseaseFrequency of relapsesSignificant adverse effectsConsolidation radiationComplete remissionConsolidation radiotherapyModality therapyCombination chemotherapyComplete responseField radiotherapyRelapse frequencyMalignant neoplasmsStandard treatmentLow doseChemotherapyRadiotherapyDiseaseRelapseAdverse effectsPatients